CliffBio
biologic

Jemperli

dostarlimab-gxly

Loss of exclusivityApril 2033projected — 12-year biologic exclusivity estimate
CompanyGlaxoSmithKline →See this company's full patent-cliff portfolio

Drug detail

Brand nameJemperli
Active ingredientdostarlimab-gxly
Strength500MG/10ML (50MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalApril 2021
Marketing statusRx

More from GlaxoSmithKline

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.